Lazabemide

Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM) . Lazabemide inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease[1].

Product Specifications

CAS Number

[103878-84-8]

Product Name Alternative

Ro 19-6327

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Lazabemide.html

Purity

99.95

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C(NCCN)=O)N=C1

Molecular Formula

C8H10ClN3O

Molecular Weight

199.64

Precautions

H302, H319

References & Citations

[1]Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12 (5) :1977-99.|[2]Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N- (2-aminoethyl) -p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50 (1) :97-102.|[3]Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62 (8) :727-37.|[4]Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50 (6) :357-62.